Editing Autosomal dominant polycystic kidney disease (section)

=== Novel Therapies ===
There are several novel therapies currently underway aimed at slowing the progression of disease in APKD. Alternative therapeutic options water therapy, use of lipid lowering agents, antiproliferative analogues and synthetic peptides.<ref name=":2" />

Water Therapy

Increased water intake downregulates vasopressin activity As a result water therapy has been explored as a potential therapeutic intervention for individuals with ADPKD, however studies have examining its role in ADPKD advancement remain unclear.<ref name=":2" />

HMG-CoA reductase inhibitors

The progression of ADPKD leads to decline in kidney function, with a marked decreased in glomerular filtration rate. As a result, treatment with statins is recommended in accordance with current guidelines for managing chronic kidney disease. The effect of statins on slowing ADPKD are inconclusive, with some trials showing a decrease in total kidney volume, while others showed no benefit on either total kidney volume or glomerular filtration rate.<ref name=":2" />

Somatostatin analogs

Somatostatin are artificial peptides designed to mimic the function of endogenous hormone that has many regulatory functions within the body including restraining cell proliferation. Small phase 2 studies have shown that somatostatin analogues are effective at reducing the rate of total kidney volume growth and preserving glomerular filtration rate.<ref name=":2" /> The use of somatostatin analogues may be restricted due to their side effects, which commonly include gastrointestinal issues such as diarrhea, abdominal discomfort, and gas, as well as conditions like gallstones and elevated blood sugar. 

Anti-proliferative agents

Proliferation of epithelial cells lining cyst resulting in cyst expansion and contributing to disease progression. As a result of this mechanism, antiproliferative agents such as tyrosine kinase inhibitor bosutinib. However, results in clinical trails have shown mixed results, with studies showing a decrease in total kidney volume. <ref name=":2" /><ref>{{Cite journal |last=Zhou |first=Julie Xia |last2=Torres |first2=Vicente E. |date=May 2023 |title=Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon |url=https://linkinghub.elsevier.com/retrieve/pii/S2949813923000034 |journal=Advances in Kidney Disease and Health |language=en |volume=30 |issue=3 |pages=245–260 |doi=10.1053/j.akdh.2023.01.003}}</ref>